{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:54:27Z","timestamp":1740135267363,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T00:00:00Z","timestamp":1600473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T00:00:00Z","timestamp":1600473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>We here report on the first observation of a C3 mutation that is related to atypical hemolytic and uremic syndrome (aHUS), which occurred in a pancreatic islet transplant patient. Immunosuppressive treatments, such as calcineurin inhibitors, have been linked to undesirable effects like nephrotoxicity.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>A 40-year-old man with brittle diabetes, who was included in the TRIMECO trial, became insulin-independent 2\u2009months after pancreatic islet transplantation. About 15\u2009months after islet transplantation, the patient exhibited acute kidney injury due to aHUS. Despite plasma exchange and eculizumab treatment, the patient developed end-stage renal disease.<\/jats:p>\n<jats:p>A genetic workup identified a missense variant (p.R592Q) in the C3 gene. In vitro, this C3 variant had defective Factor I proteolytic activity with membrane proteins as cofactor proteins, which was thus classified as pathogenic. About 1\u2009year after the aHUS episode, kidney transplantation was carried out under the protection of the specific anti-C5 monoclonal antibody eculizumab. The patient had normal kidney function, with preserved pancreatic islet function 4\u2009years later.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Pancreatic islet transplantation could have triggered this aHUS episode, but this link needs to be clarified. Although prophylactic eculizumab maintains kidney allograft function, its efficacy still needs to be studied in larger populations.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12882-020-02062-7","type":"journal-article","created":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T06:02:34Z","timestamp":1600495354000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Atypical hemolytic and uremic syndrome due to C3 mutation in pancreatic islet transplantation: a case report"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6731-8695","authenticated-orcid":false,"given":"Thibault","family":"Bahougne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9rome","family":"Olagne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Munch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Braun-Parvez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Pierrette","family":"Chenard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Fr\u00e9meaux-Bacchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Caillard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Baltzinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Greget","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Moulin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,19]]},"reference":[{"issue":"7","key":"2062_CR1","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/S2213-8587(18)30078-0","volume":"6","author":"S Lablanche","year":"2018","unstructured":"Lablanche S, Vantyghem M-C, Kessler L, Wojtusciszyn A, Borot S, Thivolet C, et al. Islet transplantation versus insulin therapy in patients with type 1 diabetes with severe hypoglycaemia or poorly controlled glycaemia after kidney transplantation (TRIMECO): a multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 2018;6(7):527\u201337.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10095","key":"2062_CR2","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","volume":"390","author":"F Fakhouri","year":"2017","unstructured":"Fakhouri F, Zuber J, Fr\u00e9meaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet (London, England). 2017;390(10095):681\u201396.","journal-title":"Lancet (London, England)"},{"issue":"7","key":"2062_CR3","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1056\/NEJMra1312353","volume":"371","author":"JN George","year":"2014","unstructured":"George JN, Nester CM. Syndromes of thrombotic Microangiopathy. N Engl J Med. 2014;371(7):654\u201366.","journal-title":"N Engl J Med"},{"issue":"4","key":"2062_CR4","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2215\/CJN.11470918","volume":"14","author":"G Bayer","year":"2019","unstructured":"Bayer G, von Tokarski F, Thoreau B, Bauvois A, Barbet C, Cloarec S, et al. Etiology and outcomes of thrombotic Microangiopathies. Clin J Am Soc Nephrol. 2019;14(4):557\u201366.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"2062_CR5","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2215\/CJN.04760512","volume":"8","author":"V Fremeaux-Bacchi","year":"2013","unstructured":"Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaim\u00e9 F, Dragon-Durey M-A, Ngo S, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8(4):554\u201362.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"2062_CR6","doi-asserted-by":"publisher","first-page":"c179","DOI":"10.1159\/000339789","volume":"120","author":"A Khwaja","year":"2012","unstructured":"Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron. 2012;120(4):c179\u201384.","journal-title":"Nephron"},{"key":"2062_CR7","doi-asserted-by":"crossref","unstructured":"Fakhouri F, Hourmant M, Campistol JM, Cataland SR, Espinosa M, Gaber AO, et al. Terminal complement inhibitor Eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial. Am J Kidney Dis. 2016;16:84\u201393.","DOI":"10.1053\/j.ajkd.2015.12.034"},{"issue":"13","key":"2062_CR8","doi-asserted-by":"publisher","first-page":"4948","DOI":"10.1182\/blood-2008-01-133702","volume":"112","author":"V Fr\u00e9meaux-Bacchi","year":"2008","unstructured":"Fr\u00e9meaux-Bacchi V, Miller EC, Liszewski MK, Strain L, Blouin J, Brown AL, et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood. 2008;112(13):4948\u201352.","journal-title":"Blood"},{"issue":"7","key":"2062_CR9","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.4049\/jimmunol.1701695","volume":"200","author":"AJ Osborne","year":"2018","unstructured":"Osborne AJ, Breno M, Borsa NG, Bu F, Fr\u00e9meaux-Bacchi V, Gale DP, et al. Statistical validation of rare complement variants provides insights into the molecular basis of atypical hemolytic uremic syndrome and C3 Glomerulopathy. J Immunol. 2018;200(7):2464\u201378.","journal-title":"J Immunol"},{"issue":"18","key":"2062_CR10","doi-asserted-by":"publisher","first-page":"4182","DOI":"10.1182\/blood-2011-10-383281","volume":"119","author":"LT Roumenina","year":"2012","unstructured":"Roumenina LT, Frimat M, Miller EC, Provot F, Dragon-Durey M-A, Bordereau P, et al. A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. Blood. 2012;119(18):4182\u201391.","journal-title":"Blood"},{"issue":"6","key":"2062_CR11","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/j.kint.2019.01.023","volume":"95","author":"A Le Clech","year":"2019","unstructured":"Le Clech A, Simon-Tillaux N, Prov\u00f4t F, Delmas Y, Vieira-Martins P, Limou S, et al. Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors. Kidney Int. 2019;95(6):1443\u201352.","journal-title":"Kidney Int"},{"issue":"8","key":"2062_CR12","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1111\/j.1600-6143.2008.02297.x","volume":"8","author":"M Le Quintrec","year":"2008","unstructured":"Le Quintrec M, Lionet A, Kamar N, Karras A, Barbier S, Buchler M, et al. Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant. 2008;8(8):1694\u2013701.","journal-title":"Am J Transplant"},{"issue":"1","key":"2062_CR13","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1172\/JCI93542","volume":"128","author":"CC Chen","year":"2018","unstructured":"Chen CC, Pouliquen E, Broisat A, Andreata F, Racap\u00e9 M, Bruneval P, et al. Endothelial chimerism and vascular sequestration protect pancreatic islet grafts from antibody-mediated rejection. J Clin Invest. 2018;128(1):219\u201332.","journal-title":"J Clin Invest"},{"issue":"3","key":"2062_CR14","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1159\/000468528","volume":"136","author":"S Milan Manani","year":"2017","unstructured":"Milan Manani S, Virz\u00ec GM, Giuliani A, Clementi A, Brocca A, Dissegna D, et al. Hemolytic uremic syndrome and kidney transplantation: a case series and review of the literature. Nephron. 2017;136(3):245\u201353.","journal-title":"Nephron"},{"issue":"1","key":"2062_CR15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40620-016-0288-3","volume":"30","author":"WJ Vande","year":"2017","unstructured":"Vande WJ, Delmas Y, Ardissino G, Wang J, Kincaid JF, Haller H. improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment. J Nephrol. 2017;30(1):127\u201334.","journal-title":"J Nephrol"},{"key":"2062_CR16","doi-asserted-by":"crossref","unstructured":"Jamme M, Raimbourg Q, Chauveau D, Seguin A, Presne C, Perez P, et al. Predictive features of chronic kidney disease in atypical haemolytic uremic syndrome. PLoS One. 2017;12(5):e0177894.","DOI":"10.1371\/journal.pone.0177894"},{"issue":"7","key":"2062_CR17","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1111\/j.1600-6143.2012.04051.x","volume":"12","author":"S Krid","year":"2012","unstructured":"Krid S, Roumenina LT, Beury D, Charbit M, Boyer O, Fr\u00e9meaux-Bacchi V, et al. Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH\/CFHR1 hybrid protein. Am J Transplant. 2012;12(7):1938\u201344.","journal-title":"Am J Transplant"},{"issue":"3","key":"2062_CR18","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/ajt.12077","volume":"13","author":"M Le Quintrec","year":"2013","unstructured":"Le Quintrec M, Zuber J, Moulin B, Kamar N, Jablonski M, Lionet A, et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant. 2013;13(3):663\u201375.","journal-title":"Am J Transplant"},{"issue":"8","key":"2062_CR19","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1681\/ASN.2006080811","volume":"18","author":"A-L Sellier-Leclerc","year":"2007","unstructured":"Sellier-Leclerc A-L, Fremeaux-Bacchi V, Dragon-Durey M-A, Macher M-A, Niaudet P, Guest G, et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2007;18(8):2392\u2013400.","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"2062_CR20","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1007\/s00467-014-2817-4","volume":"29","author":"S Johnson","year":"2014","unstructured":"Johnson S, Stojanovic J, Ariceta G, Bitzan M, Besbas N, Frieling M, et al. An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome. Pediatr Nephrol. 2014;29(10):1967\u201378.","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"2062_CR21","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1056\/NEJMc0809959","volume":"360","author":"RA Gruppo","year":"2009","unstructured":"Gruppo RA, Rother RP. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med. 2009 Jan 29;360(5):544\u20136.","journal-title":"N Engl J Med"},{"issue":"12","key":"2062_CR22","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1111\/j.1600-6143.2012.04252.x","volume":"12","author":"J Zuber","year":"2012","unstructured":"Zuber J, Le Quintrec M, Krid S, Bertoye C, Gueutin V, Lahoche A, et al. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant. 2012;12(12):3337\u201354.","journal-title":"Am J Transplant"},{"issue":"1","key":"2062_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","volume":"31","author":"C Loirat","year":"2016","unstructured":"Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31(1):15\u201339.","journal-title":"Pediatr Nephrol"},{"key":"2062_CR24","unstructured":"Zuber J, Frimat M, Caillard S, Kamar N, Gatault P, Petitprez F, et al. Use of highly individualized complement blockade has revolutionized clinical outcomes after kidney transplantation and renal epidemiology of atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2019;ASN.2019040331(12):2449\u201363."},{"issue":"7","key":"2062_CR25","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1111\/j.1600-6143.2010.03156.x","volume":"10","author":"M Noris","year":"2010","unstructured":"Noris M, Remuzzi G. Thrombotic Microangiopathy after kidney transplantation. Am J Transplant. 2010;10(7):1517\u201323.","journal-title":"Am J Transplant"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-02062-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-020-02062-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-02062-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,18]],"date-time":"2021-09-18T23:05:30Z","timestamp":1632006330000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-020-02062-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,19]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2062"],"URL":"https:\/\/doi.org\/10.1186\/s12882-020-02062-7","relation":{},"ISSN":["1471-2369"],"issn-type":[{"type":"electronic","value":"1471-2369"}],"subject":[],"published":{"date-parts":[[2020,9,19]]},"assertion":[{"value":"15 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TRIMECO study is registered with , number NCT01148680. TRIMECO study was approved by the French Committee for the Protection of Persons Participating in Biomedical Research (approval number 09-CHUG-21), and clinical trial authorization was obtained from the French National Competent Authority (2008-A01554\u201351). Written informed consent was obtained from all patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"VFB has received consultancy, lecture fees, or travel support from Alexion Pharmaceuticals, Roche, Apellis. The other authors have no potential conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"405"}}